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Abstract
Hepatitis C virus causes acute and chronic hepatitis and can lead to permanent liver damage and hepatocellular
carcinoma (HCC) in a significant number of patients via oxidative stress, insulin resistance (IR), fibrosis, liver cirrhosis
and HCV induced steatosis. HCV induced steatosis and oxidative stress causes steato-hepatitis and these pathways
lead to liver injury or HCC in chronic HCV infection. Steatosis and oxidative stress crosstalk play an important role
in liver damage in HCV infection. This Review illustrates viral and host factors which induce Oxidative stress,
steatosis and leads toward HCC. It also expresses Molecular cascade which leads oxidative stress and steatosis to
HCC.
Introduction
Hepatitis C virus causes acute and chronic hepatitis [1]
an can leads to HCC via oxidative stress, insulin resis-
tance (IR), fibrosis, liver cirrhosis and HCV induced
steatosis [2]. HCV is a major health problem, almost
350 million individuals are chronically HCV infected [3]
and 10% of the Pakistani population is chronically
infected with this viral pathogen [4]. Approximately 40-
60% of HCV infected individuals leads to chronic liver
disease [5], and prevalence of HCV associated HCC is
higher in Pakistan as compare to the rest of world [6,7].
HCV is an enveloped positive-single stranded RNA
virus 9.6 kb in length consisting of (Core, E1, E2 and
possibly p7) proteins and nonstructural (NS2, NS3,
NS4A, NS4B, NS5A and NS5B) viral proteins [8,9].
HCV Core is known as the inducer of steatosis, oxida-
tive stress and HCC [10]. E1 and E2 are involved in
virus attachment with the cells and are considered to be
the first viral protein comes in contact with the cells
[11]. p7 is possibly concerned with ion channel and
virus assembly [12]. HCV has six genotypes and 52 sub-
types mainly genotypes in the different region of the
w o r l da r e( 1 a ,b ,c ,2 a ,b ,c ,3 a ,b ,4 a ,5 a ,6 a ) .D u et o
absence of proofreading function of the RNA-dependent
RNA-polymerase (NS5B), HCV has a high mutation rate
and exists as genetically heterogeneous quasispecies in
individual patients [13,14]. The genetic diversity is more
than 30% in different genotypes and 20% in subtypes.
Variations in amino acid sequence of different HCV
genotypes cause difference in severity of pathogenesis.
Recent studies have shown variable responses for inter-
feron (IFN)-ribavirin combination therapy, oxidative
stress/steatosis and insulin resistance due to the amino
acid substitutions in the HCV Core region of different
HCV genotypes.
HCV genotype 3a is mainly prevalent in Pakistan fol-
lowed by 3b and 1a [15]. Moreover, a strong correlation
between chronic HCV infection and HCC in Pakistan
associated with genotype 3a has been observed which is
not been observed in relation to any other genotype [6].
HCV genotype 3a is mostly involved in HCV induced
steatosis [16]. HCV induced steatosis and oxidative
stress causes steatohepatitis [17] and these pathways
leads to liver injury or HCC in chronic HCV infection
[10,18]. Steatosis and oxidative stress crosstalk play
important role in liver damage in HCV infection [19].
Oxidative stress is a key contributor in HCV-induced
pathogenesis (Tardif et al., 2005). Previous reports
showed that HCV Core protein regulates gene expres-
sion and alter cell signaling pathways [20] leading to
oxidative stress, liver steatosis and eventually HCC [21].
HCV Core protein also up regulates cyclooxygenase-2
(COX-2) expression in hepatocytes and causes oxidative
stress leading to HCC [22,23]. Cellular genes inducible
nitric oxide synthetase (iNOS) COX-2 and Vascular Epi-
dermal Growth Factor (VEGF) regulate cellular growth
and over expression of these genes has carcinogenic
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esis growth factors via VEGF [25-27] and it has also
been revealed that the over expression of COX-2 acti-
vates Akt by phosphorylation of Akt in human HCC
[28]. Akt acts as a key signal mediator, which modulates
cell survival and proliferation [29,30]. Different studies
have shown the effect of HCV on these genes but effect
of HCV genes on these cellular genes which are crucial
for HCV pathogenesis has not been evaluated
completely.
Steatosis, the most common cause of abnormal liver
function, is a pathological condition in which simple tri-
glyceride accumulation in hepatocytes cause hepatic
steatosis that leads to HCC and other liver diseases
(Tetri and Caldwll, 2003). In fatty acid synthesis path-
way loss of adiponectin Receptor (Adipo R2) due to
HCV activates of the enzyme acetyl-CoA carboxylase
(ACC) [31] a rate-limiting enzyme for fatty acid synth-
esis. ACC catalyzes synthesis of malonyl CoA that is
further converted into saturated fatty acids by the action
of fatty acid synthase (FAS) [32]. In addition, the tran-
scription factors such as sterol regulatory element bind-
ing protein (SREBP) and peroxisomal proliferator
activator receptor-a (PPAR-a) are also the key player in
both lipogenesis and fatty acid oxidation pathways.
SREBP activates the entire gene involved in lipogenesis
[33]. A major function of PPAR-a is to control fatty
acid oxidation and activation and its deficiency results
in defective fatty acid oxidation [34,35]. It has been
demonstrated that HCV proteins may accumulate trigly-
cerides in hepatocytes by modulating the fatty acid
synthesis pathway which leads to steatosis [32]. How-
ever, the mechanism involved in the HCV induced stea-
tosis is still not clear.
Apoptosis is fundamental process for the control and
elimination of viral infections. The impact of apoptosis
in chronic HCV infection is not well understood. It may
be harmful by triggering liver fibrosis, or essential for
viral elimination [36]. HCV proteins, particularly Core
and NS5A protein have both pro- and anti-apoptotic
effects. It is not known which HCV protein affects apop-
tosis and whether the infectious virions act pro- or anti-
apoptotic. E1 and E2 are involved in virus attachment
with the cells [37].
Oxidative stress
Oxidative stress refers to the oxidation-reaction-domi-
nant state of the living body induced by an imbalance
between the oxidation reaction caused by reactive oxy-
gen species (ROS) and the anti-oxidation reaction. Main
ROS include superoxide (O2-), hydrogen peroxide
(H2O2) and the hydroxyl radical (HO) [17]. Oxidative
stress has emerged as a key contributor in the develop-
ment and progression of many pathological conditions,
including HCV-induced pathogenesis of liver [38].
Mainly in liver cells NO production which is induced by
iNOS enzyme which is activated in inflammatory
process.
HCV induced oxidative stress
Oxidative stress is produced by inflammatory progres-
sions that occur in hepatitis via immunological mechan-
isms. In addition, in HCV infectious disease, viral
proteins have some functions in the induction of oxida-
tive stress. In HCV infection, ROS are produced by
NADPH oxidize and xanthine oxidase in neutrophils
and macrophages [39]. It have been also demonstrated
that oxidative stress plays an important role in CHC
[40]. In the presence of hepatic steatosis, IR and
increased levels of some cytokines, all of which are also
stimulated by viral protein expression, oxidative stress is
enhanced in HCV infection. In addition, HCV produced
ROS also in hepatocytes in response to release of
inflammatory cytokine from inflammatory cells [18,41].
A pathological relationship between oxidative stress and
HCV infection is observed, the causes of oxidative stress
in HCV infection are considered to include various fac-
tors such as mitochondrial damage, lipid accumulation
and ER stress in the liver. Different studies revealed that
viral proteins, mainly the HCV Core protein, cause oxi-
dative stress. In this sense, inflammation in CHC is con-
sidered to be qualitatively different from inflammation
observed in other types of hepatitis such as autoimmune
hepatitis or hepatitis [17].
HCV structural genes and oxidative stress
In addition to nucleocapsid formation, HCV Core pro-
tein also modulates gene transcription, cell proliferation,
cell death, and cell signaling, interferes with lipid meta-
bolism and suppresses host immune response [20]. Core
is an important pathogenic determinant of HCV
induced oxidative stress leading to liver steatosis, and
HCC [21,42]. In addition, it is notable that in HCV
infection the viral proteins themselves as well as inflam-
mation due to hepatitis are regarded as a cause of oxida-
tive stress [23]. HCV Core protein is known as the
inducer of steatosis, oxidative stress and HCC [10].
HCV structural genes, particularly the Core protein,
have different functions with respect to host cells [43]
and are closely related to oxidative stress. Core protein
is also able to up regulate ROS production by induced
nitric oxide Synthetase (iNOS) which activates cyclooxy-
genase-2 (COX-2) expression in hepatocytes derived
cells, providing a potential mechanism for oxidative
stress leading to HCC [22,23]. The Core protein was
found to have a variety of actions, including the induc-
tion of oxidative stress and accumulation of lipids, in
cultured cells and transgenic mice [10,23] and an
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mitochondrial electron transport system was observed in
Core-protein-expressing cells [23]. Mitochondrial DNA,
which has no protective proteins such as histone, is sus-
ceptible to damage by ROS in response to HCV and
causes Apoptosis [44,45] and could also increase oxida-
tive stress caused by damage of the electron transport
system. Core is an important pathogenic determinant of
HCV induced oxidative stress. It is also able to up regu-
late COX-2 expression in hepatocyte derived cells, pro-
viding a potential mechanism for hepatic fibrosis during
chronic HCV infection [23].
Cellular genes involved in HCV induced oxidative stress
and HCC
iNOS
In an inflammation, iNOS is induced in macrophages
and hepatocytes [46,47]. iNOS is related to a high-out-
put pathway of oxidative stress and is responsible for
various pathological processes [25]. In fact, iNOS synth-
esis correlates with intra hepatic viral load in CHC [48].
NO causes cellular damage upon its reaction to O2 and
finally produced nitro tyrosine, which was observed in
association to inflammation severity in CHC tissue [49]
suggesting that the production of both NO and ROS
increased. ROS and RNS are produced as defense factors
against viral infection, but these. ROS and RNS also
have cytotoxic effects. Over production of iNOS and
COX-2 have carcinogenic effects achieved either directly
or by producing mediator that regulate cellular growth
[25-27]. Elevated NO production has been implicated as
a cause of tissue damage by inflammation, thus contri-
buting to liver tumor promotion [50]. NO has been
shown to induce oxidative DNA damage and inhibit
DNA repair [51]. The expression of both COX-2 and
iNOS was significantly elevated in HCV-positive HCCs.
These findings suggest that combined expression of
iNOS and COX-2 may play an important role in the
prognosis of HCV-positive HCC patients. Rahman et al.
in 2001 examined COX-2 expression significantly corre-
lated with iNOS expression playing an important role in
prognosis of HCV-positive HCC patients that could be
partially attributable to modulation of angiogenesis by
COX-2 and a combined negative expression of iNOS
and COX-2 had a significant impact on patient survival.
COX-2
Two isoforms of COXs have been identified, COX-1 and
COX-2, both catalyzing the same enzymatic reaction.
Despite the structural similarity, COX-1 and COX-2 are
regulated and function differently [52]. COX-2 is not
constitutively expressed, but is rapidly induced by both
inflammatory and mitogenic stimuli resulting in
increased Prostaglandins (PG) synthesis in neoplastic
and inflamed tissues. PGs play a central role in
inflammation, and COX is the key enzyme in the con-
version of arachidonic acid to prostaglandins. COX-2 is
induced by a variety of factors such as ROS, cytokines,
growth factors and tumor promoters and has been con-
nected to inflammation and the inhibition of apoptosis
leading to carcinogenesis [53,54]. The expression of
COX-2 in HCC was found to correlate with the levels of
several key molecules implicated in carcinogenesis such
as iNOS activate VEGF and p-Akt [55,56]. iNOS and
COX-2 have carcinogenic effects achieved either directly
or by producing mediator that regulate cellular growth
[24]. COX-2 can induce angiogenesis growth factors via
VEGF [25-27].
Upregulation of COX-2 has been detected in HCC
[25,55,57]. COX-2 have carcinogenic effects [58,59]
achieved either directly or by producing mediators that
regulate cellular growth. COX-2 can induce angiogenesis
via VEGF and PG production [25-27] and can also inhi-
bit apoptosis by inducing the antiapoptotic factor Bcl-2
as well as activating antiapoptotic signaling through
Akt/PKB. Phospho-Akt-Ser473 is also upregulated and
causes the activation of COX-2 expression in liver cells.
COX-2 plays an important role in VEGF-induced angio-
genesis via p38 and JNK kinase activation pathways as
VEGF-induced cell proliferation was significantly
reduced when transfected with COX-2 siRNA (34.12 ±
5.81%) [60]. COX-2 expression in Huh-7 cell line was
inhibited by selective COX-2 inhibitor (SC-58635) or
COX-2 siRNA and dramatically suppressed the prolif-
eration, migration, and differentiation in vitro and in
vivo. An approximately 78% reduction of VEGF level
has been found in COX-2 siRNA treated Huh-7 con-
f i r m e dt h er o l eo fC O X - 2i ni n d u c t i o no fV E G F .M o r e -
over, COX-2/PGE2/EP/VEGF pathway possibly also
contributes to tumor angiogenesis in HCC [61]. COX-2-
specific siRNAs were electroporated into SNU-387 cells
and significant, sequence specific reductions in COX-2
expression, PGE2 production, and cell proliferation were
observed (Park et al., 2006). Recent evidence indicates
that COX-2 modulates angiogenesis either by augment-
ing the release of angiogenic peptides by tumor cells or
by directly increasing the production of PGs [24,62].
PGE 2
PGs play a central role in inflammation, and COX is the
key enzyme in the conversion of arachidonic acid to PG.
The first step in the formation of PG is the liberation of
arachidonic acid (AA) from membrane-bound phospho-
lipids COXs [63,64]. It appears that inflammation-
mediated induction of COX-2 may represent a pivotal
step in hepatocarcinogenesis. Recent experimental evi-
dence suggests that increased COX-2 expression and
PG production may contribute to the development of
HCC. Several recent studies indicate that the COX-2/
PGE2 pathway is involved in HCC cell invasion [65,66].
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mote the growth of human HCC cells. In cultured HCC
cells, over expression of COX-2 or treatment with PGE2
enhances VEGF production and this effect is blocked by
inhibition of COX-2 [26]. Transfection of human HCC
cell lines Hep3B and HepG2 with COX-2 expression
vector or treatment with exogenous PGE2 induced
phosphorylation of serine/threonine protein kinase B
(Akt) and enhanced cell growth [28]. The observations
that celecoxib inhibits the production of PGE2 in HCC
cells and that COX-2 or PGE2 partial protects against
celecoxib-induced apoptosis suggest the involvement of
COX-2 inhibition in celecoxib-induced inhibition of
HCC cell growth [28]. Therefore, in addition to hepato-
carcinogenesis, COX-2-controlled PGE2 production sig-
naling may also contribute to the pathogenesis of
chronic hepatitis and cirrhosis.
p Akt
The expression of COX-2 in HCCs was found to corre-
late with the levels of several key molecules implicated in
carcinogenesis, such as p-Akt [28], VEGF [26,27] and
iNOS [25,28]. Leng et al (2003) showed a positive corre-
lation between the expression of COX-2 and phosphory-
lated Akt/Protein kinase B (PKB) in human HCC,
suggesting a potential role of Akt in COX-2-mediated
hepatocarcinogenesis. The level of COX- 2 expression
and Akt phosphorylation is positively correlated in cul-
tured HCC cells and in human liver cancer tissues.
Furthermore, inhibition of Akt activation by phosphati-
dylinositol 3-kinase (PI3-kinase) inhibitor LY294002 sig-
nificantly decreased the viability of HCC cells [28]. These
findings suggest an important role of Akt activation in
COX-2-induced HCC cell survival. The observations that
celecoxib treatment decreased the phosphorylation of
Akt and that inhibition of Akt reduced HCC cell viability
suggest that involvement of pAkt in HCC [28,30].
VEGF
Vascular Epidermal Growth Factor synthesis occurs via
oxidative stress and calcium signaling induced by HCV
gene expression. VEGF the most potent angiogenic fac-
tor for tumor angiogenesis is believed to be involved in
COX-2-mediated angiogenesis [58,59]. COX-2 can
induce angiogenesis via VEGF and PG production.
Moreover, COX-2/PGE2/EP/VEGF pathway possibly
also contributes to tumor angiogenesis in HCC (Zhao et
al., 2007). There is also compelling evidence suggesting
an important role of angiogenesis in COX-2-mediated
hepatocarcinogenesis. COX-2 has been shown to induce
angiogenesis via VEGF [62,67]. Two recent studies show
that elevated COX-2 expression correlates with
increased VEGF level and micro vascular density in
human HCCs [26,27]. There is also evidence that the
COX-2 inhibitor reduces the production of VEGF, a
potent stimulator of angiogenesis in Huh-7 cells [26].
Mechanism of oxidative stress leading to HCC
Oxidative stress has emerged as a key contributor in the
development and progression of many pathological con-
ditions, including HCV-induced pathogenesis of liver
(Tardif et al., 2005). The expression of COX-2 in HCC
was found to correlate with the levels of several key
molecules implicated in carcinogenesis such as iNOS,
VEGF and p-Akt [25,55]. COX-2 and iNOS have carci-
nogenic effects achieved either directly or by producing
mediator that regulate cellular growth [24]. COX-2 can
induce angiogenesis growth factors via VEGF (Rahman
et al., 2001; Cheng et al., 2004; Tang et al., 2005).
VEGF is also stimulated by a number of other inflam-
matory mediators including NO and certain cytokines.
Previously, it has been shown that the over expression
of COX-2 activates Akt in human HCC via a p13-
kinase-dependent mechanism [28]. Akt acts as an
important signal mediator, which regulates cell survival
and proliferation [29,30]. High nitric oxide production
has been concerned as a cause of tissue damage by
inflammation, thus contributing to liver tumor promo-
tion [50]. The expression of both COX-2 and iNOS was
significantly elevated in HCV-positive HCCs; the level of
COX-2 expression was significantly correlated with
iNOS expression [25]. These findings suggest that com-
bined expression of iNOS and COX-2 may play an
important role in the prognosis of HCV-positive HCC
patients. A few studies have revealed that COX-2
expression is correlated with VEGF expression in HCC
[25-27]. COX-2/PGE2/EP/VEGF pathway possibly also
contributes to tumor angiogenesis in HCC (Zhao et al.,
2007). Expression of HCV sub genomic replicons or
replicon RNA in human HCC cells increases COX-2
expression at the level of transcription through HCV-
induced oxidative stress and subsequent activation of
NF-kB (Cheng et al., 2004). The positive correlation
between COX-2 and VEGF in the noncancerous liver
tissues (Tang et al., 2005) suggests that COX-2 may also
be involved in the angiogenesis in chronic liver disease
through the VEGF pathway.
HCV induced oxidative stress and steatosis lead to HCC
Oxidative stress and steatosis is supposed to play a pivo-
tal role in the development of liver injury or HCC in
chronic HCV infection (Figure 1) [10,18]. It has been
reported that HCV genotype 3a is mostly involved in
oxidative stress and HCV induced steatosis [16], which
both contributes in the development of HCC [21,42,68].
S t u d i e sh a v es h o w nt h eo c c u r r e n c eo fo x i d a t i o ns t r e s s
and lipid peroxidation in CHC patients leads to HCC
[69]. HCC is one of the most common causes of malig-
nancy-related death in Africa and Asia (Koga, 2003).
The role of oxidative stress in the progression of chronic
hepatitis and hepatocarcinogenesis is greater in hepatitis
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autoimmune hepatitis. The additive effects of oxidative
stress caused by the inflammatory process and that
induced by HCV proteins may, furthermore, exert
synergistic effects with alterations in intracellular signal-
ing systems such as MAPK, which are also induced by
HCV proteins. These synergistic effects may be respon-
sible for rare characteristics, that is, the high incidence
and multicentric nature of hepatocarcinogenesis in HCV
infection. According to other proposed mechanism
HCV Core and NS proteins may accumulate ROS which
results in the peroxidation of membrane lipids and
structural proteins, which are involved in the trafficking
and secretion apparatuses, which block the VLDL secre-
tion and causes mitochondrial dysfunction, DNA and
cellular protein damage and further aggravate oxidative
stress [42]. ROS production causes kupffer cells bursting
which results in release of cytokines: TNFa, IL6 and IL8
[15]. TNFa down regulate the adiponectine thus, indu-
cing IR and steatosis.
In human HCV genotype 3, which is most common in
Pakistan, is more commonly associated withs t e a t o s i s
[70]. HCV induced Steatosis and oxidative stress is the
most frequent cause of abnormal liver function. The
Core protein was found to have a variety of actions,
including the induction of oxidative stress and accumu-
lation of lipids, in cultured cells and transgenic mice
[10,23]. An increased ROS production and increased
levels of intrahepatic peroxide lipids was observed in the
Core gene transgenic mice as compare to control mice
also show increased oxidative stress. Increased ROS pro-
duction has been reported due to ß-oxidation in the
mitochondria and peroxisomes or the metabolism of
fatty acids by cytochrome P450 2E1 (CYP2E1) in micro-
somes is promoted under an excessive load of fatty
acids (Day and James. 1998: Weltman et al., 1998). In
HCV infection intrahepatic fat accumulation possibly
increases ROS production as in HCV induced steatosis.
Because hepatic steatosis in chronic hepatitis C was
reported to be a cause for disease development (Czaja et
al., 1998) increased oxidative stress related with hepatic
steatosis is most probably involved in disease progres-
sion. Oxidative stress markers, 8-Hydroxy deoxyguano-
sine (8-OHdG) and peroxylipids were found to be
decreased in PPAR-a KO Core gene transgenic mice
which contributes to increased production of oxidative
stress [10]. HCV Core protein down regulates the adipo-
nectine receptor which further down regulates PPAR
and up regulates JNK, AP-1 and cyclin D1 which results
in, activation of cell growth signaling leads to HCC. On
the other hand down regulation of adiponectine recep-
tor also activates hepatic cells HSC due to which net
collagen synthesis increases which lead to fibrosis and
HCC.
HCV and disease progression
HCV can leads to IR, fibrosis, liver cirrhosis and steato-
sis in a substantial number of patients [71-73]. Some
studies showed that steatosis is more associated with
fibrosis progression in HCV patients infected with geno-
type 3 i.e. patients with viral induced steatosis [74,75].
Other studies showed that metabolic steatosis is signifi-
cantly associated with more sever fibrosis [76,77]. High
level of TNF-a in CHC patient has been shown to
Figure 1 Schematic representation of HCV to HCC.
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Several studies reveal that IR is associated with non-
alcoholic steatohepoatitis (NASH) and is also associated
with a high risk of HCC that means IR increases the
risk of chronic liver diseases and HCC. Moriya and col-
leagues showed that transgenic expression of Core pro-
tein leads to extensive steatosis, increased oxidative
stress, mitochondrial injury and HCC in aging mice
[21]. HCV induced steatosis and oxidative stress causes
steatohepatitis [17] and these pathways leads to liver
injury or HCC in chronic HCV infection [10,18]. Steato-
sis and oxidative stress crosstalk play important role in
liver damage in HCV infection.
Conclusion
The review describes viral and host factors which induce
Oxidative stress, steatosis and leads toward HCC. Mole-
cular cascade that leads to oxidative stress and steatosis
to HCC has also been illustrated. In future, these bio-
markers and therapeutic tartget can be used in the treat-
ment of hepatocellular carcinoma.
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